After PBM Reform: Are States Equipped to Enforce the Laws They Pass?

By Ron Lanton III, Esq.

State legislatures have made considerable progress in regulating pharmacy benefit managers (PBMs). Laws addressing reimbursement, patient steering, pharmacy network participation, transparency and auditing practices have expanded state oversight of the prescription drug marketplace.

The next challenge is enforcement. Do state regulatory agencies have the resources, technical expertise and institutional knowledge to oversee the business practices these laws are intended to regulate?

From Legislation to Enforcement

The governor's signature does not necessarily resolve the problems that prompted legislation. State agencies may still need to develop regulations, establish reporting requirements, create investigative procedures and determine how violations will be addressed.

This is where legislative intent can be tested. Decisions made during rulemaking can affect the scope of pharmacy protections, the obligations imposed on PBMs and the remedies available when violations occur.

Healthcare stakeholders should remain engaged well beyond the legislative process.

Developing Institutional Knowledge

Regulating PBMs requires an understanding of pharmacy economics, reimbursement methodologies, network contracts, manufacturer rebates, drug distribution and corporate affiliations.

State regulators must be able to analyze these business arrangements, identify potential violations and determine whether individual complaints reflect broader commercial practices.

Building that expertise requires specialized personnel, adequate funding and access to reliable data. States must also consider how institutional knowledge will be preserved when experienced regulatory personnel leave or administrative priorities change.

What Effective Enforcement Requires

As states expand their PBM oversight responsibilities, policymakers should consider five questions:

  • Does the agency have personnel with pharmacy and reimbursement expertise?

  • Can regulators independently examine PBM contracts and transaction data?

  • Are complaint and appeal procedures accessible to pharmacies?

  • Can regulators identify recurring violations across multiple businesses?

  • Are enforcement remedies sufficient to deter future violations?

States should also share investigative practices and regulatory experience with other jurisdictions. Lessons from existing enforcement programs could reduce implementation costs and help newer programs avoid similar difficulties.

Beyond Legislative Victories

The effectiveness of PBM reform should be measured by compliance, enforcement outcomes and improvements in pharmacy and patient access.

For policymakers, the responsibility extends beyond passing legislation. For PBMs, new laws require ongoing review of contractual and operational practices. For pharmacies, understanding how to document violations and pursue available remedies becomes equally important.

The next phase of PBM reform will depend on whether states can build and maintain the regulatory infrastructure necessary to enforce their laws.

How Lanton, Lanton & Sosa Law Can Help

Lanton, Lanton & Sosa Law advises pharmacies, healthcare organizations, pharmaceutical companies and industry associations on PBM regulation, reimbursement disputes, commercial agreements, regulatory compliance and government affairs.

Our experience in legislative advocacy, administrative rulemaking and pharmacy law allows us to assist clients throughout the policy process, from legislative development and regulatory implementation to compliance assessments and enforcement matters.

Learn more about our Pharmacy Law practice.

Previous
Previous

FDA Extends DSCSA Exemptions Through 2027: What Pharmacies and Drug Distributors Need to Know

Next
Next

What Startups Need to Know Before Hiring Their First Employees